Table 2.
Registered Clinical Trials using T-cell Related Immunotherapy for Osteosarcoma.
| Trial ID | Type of Immunotherapy | Target Disease | Techniques | Phase | Status |
|---|---|---|---|---|---|
| NCT01241162 | DC vaccine | Osteosarcoma, other cancer |
DC vaccine, Decitabine | 1 | Completed without result |
| NCT01803152 | DC vaccine | Osteosarcoma, other sarcoma |
DC vaccine, Gemcitabine | 1 | Active, not recruiting |
| NCT02107963 | CAR T-cell | Osteosarcoma, other cancer | GD2-CAR, AP1903, Cyclophosphamide | 1 | Completed without result |
| NCT01953900 | CAR T-cell | Osteosarcoma, Neuroblastoma | GD2-CAR, VZV vaccine, Fludarabine, Cyclophosphamide | 1 | Active, not recruiting |
| NCT03635632 | CAR T-cell | Osteosarcoma, other cancer | C7R-GD2-CAR, Fludarabine, Cyclophosphamide | 1 | Recruiting |
| NCT03356782 | CAR T-cell | Osteosarcoma, other sarcoma |
Each sarcoma specific CAR-T-cell | 1/2 | Recruiting |
| NCT03628209 | Anti-PD-1 antibody | Osteosarcoma | Nivolumab, Azacitidine, surgery | 1/2 | Recruiting |
| NCT03277924 | Anti-PD-1 antibody | Osteosarcoma, other sarcoma |
Nivolumab, Sunitinib | 1/2 | Recruiting |
| NCT04294511 | Anti-PD-1 antibody | Osteosarcoma | Camrelizumab, Neoadjuvant chemotherapy | 2 | Recruiting |
| NCT03359018 | Anti-PD-1 antibody | Osteosarcoma | SHR-1210, Apatinib | 2 | Completed |
| NCT04351308 | Anti-PD-1 antibody | Osteosarcoma | Camrelizumab, MAPI, Apatinib | 2 | Recruiting |
| NCT03013127 | Anti-PD-1 antibody | Osteosarcoma | Pembrolizumab | 2 | Active, not recruiting |
| NCT04044378 | Anti-PD-1 antibody | Osteosarcoma | Camrelizumab, Famitinib, Isosfamide | 2 | Withdrawn (Toxicity) |
| NCT03676985 | Anti-PD-L1 antibody | Osteosarcoma | ZKAB001 | 1/2 | Recruiting |
| NCT04359550 | Anti-PD-L1 antibody | Osteosarcoma | ZKAB001 | 3 | Not yet recruiting |
| NCT03006848 | Anti-PD-L1 antibody | Osteosarcoma | Avelumab | 2 | Active, not recruiting |
| NCT02500797 | Anti-PD-1 a/o L1 antibody | Osteosarcoma, other cancer | Nivolumab, Ipilimumab | 2 | Active, not recruiting |
| NCT02982486 | Anti-PD-1 a/o L1 antibody | Osteosarcoma, other cancer | Nivolumab, Ipilimumab | 2 | Not yet recruiting |
| NCT02815995 | Anti-PD-1/L1 antibody | Osteosarcoma, other sarcoma |
Durvalumab, Tremelimumab | 2 | Active, not recruiting |
| NCT04074564 | DC vaccine, Anti-PD-1 antibody | Osteosarcoma, other sarcoma |
MASCT-I, anti-PD-1 antibody, Apatinib | 1 | Not yet recruiting |
VZV, varicella-zoster virus; a/o, and/or.